Literature DB >> 26477683

Immunotherapy and tumor microenvironment.

Haidong Tang1, Jian Qiao1, Yang-Xin Fu2.   

Abstract

Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CAR T-cell therapy; Checkpoint blockade; Chemokine; Cytokine; Tumor microenvironment; Tumor-infiltrating immune cells

Mesh:

Substances:

Year:  2015        PMID: 26477683      PMCID: PMC4725050          DOI: 10.1016/j.canlet.2015.10.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  89 in total

Review 1.  Chemokines and cell migration in secondary lymphoid organs.

Authors:  J G Cyster
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 2.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 3.  Development and maturation of secondary lymphoid tissues.

Authors:  Y X Fu; D D Chaplin
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

4.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 5.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 6.  A new era for cancer immunotherapy based on the genes that encode cancer antigens.

Authors:  S A Rosenberg
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

7.  Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.

Authors:  S Sharma; M Stolina; J Luo; R M Strieter; M Burdick; L X Zhu; R K Batra; S M Dubinett
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

8.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Authors:  L Diehl; A T den Boer; S P Schoenberger; E I van der Voort; T N Schumacher; C J Melief; R Offringa; R E Toes
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

9.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

10.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

View more
  94 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

Review 2.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

3.  In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.

Authors:  Yanhua Bai; Ting Guo; Xiaozheng Huang; Qi Wu; Dongfeng Niu; Xinqiang Ji; Qin Feng; Zhongwu Li; Kennichi Kakudo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

Review 4.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

5.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

6.  The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment.

Authors:  Jiezuan Yang; Guoping Sheng; Dangsheng Xiao; Haiyan Shi; Wei Wu; Haifeng Lu; Hongcui Cao; Lanjuan Li
Journal:  Cell Mol Immunol       Date:  2016-02-22       Impact factor: 11.530

7.  Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors:  Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 8.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

9.  Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Authors:  Stephen Iwanowycz; Junfeng Wang; Johnie Hodge; Yuzhen Wang; Fang Yu; Daping Fan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

10.  PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Authors:  Haidong Tang; Yong Liang; Robert A Anders; Janis M Taube; Xiangyan Qiu; Aditi Mulgaonkar; Xin Liu; Susan M Harrington; Jingya Guo; Yangchun Xin; Yahong Xiong; Kien Nham; William Silvers; Guiyang Hao; Xiankai Sun; Mingyi Chen; Raquibul Hannan; Jian Qiao; Haidong Dong; Hua Peng; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.